VivoSim Labs, Inc. (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.
The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology. These platforms support a range of applications from high-throughput screening and mechanism-of-action studies to personalized medicine initiatives, allowing pharmaceutical and biotechnology customers to accelerate research timelines and reduce reliance on animal testing. VivoSim Labs also offers custom assay development, contract research services, and collaborative partnerships to address unique project requirements.
Founded to leverage advances in cellular biology and biofabrication, VivoSim Labs has positioned itself as an innovator in the life sciences tools market. Headquartered in the United States, the company serves a global customer base spanning North America, Europe and Asia. With a focus on expanding its product pipeline, scaling manufacturing capabilities and forging strategic alliances, VivoSim Labs aims to enhance the predictability of preclinical studies and drive more efficient drug development pathways.
AI Generated. May Contain Errors.
